Results 221 to 230 of about 112,698 (266)
Some of the next articles are maybe not open access.
Hematology, 2003
AbstractChronic myeloid leukemia (CML) was the first human malignancy to be associated with a specific genetic lesion, the Philadelphia chromosome, harboring the BCR-ABL oncogene. Since then, it has become a paradigm for the discovery of molecular mechanisms and targeted therapeutic approaches in the field of hematologic neoplasias. The past 5 years or
Junia V, Melo +2 more
openaire +2 more sources
AbstractChronic myeloid leukemia (CML) was the first human malignancy to be associated with a specific genetic lesion, the Philadelphia chromosome, harboring the BCR-ABL oncogene. Since then, it has become a paradigm for the discovery of molecular mechanisms and targeted therapeutic approaches in the field of hematologic neoplasias. The past 5 years or
Junia V, Melo +2 more
openaire +2 more sources
Current Opinion in Hematology, 1998
Progress has been made in understanding BCR-ABL-positive leukemias. A new transcript (p230BCR-ABL) has been characterized that is associated with Ph-positive chronic neutrophilic leukemia. The ATM protein appears to be a regulator of ABL activity in response to irradiation damage.
M W, Deininger, J M, Goldman
openaire +2 more sources
Progress has been made in understanding BCR-ABL-positive leukemias. A new transcript (p230BCR-ABL) has been characterized that is associated with Ph-positive chronic neutrophilic leukemia. The ATM protein appears to be a regulator of ABL activity in response to irradiation damage.
M W, Deininger, J M, Goldman
openaire +2 more sources
Olverembatinib in chronic myeloid leukemia
Drugs of Today, 2022The introduction of tyrosine kinase inhibitors (TKIs) represents a new era in the management of chronic myeloid leukemia (CML). Despite their long clinical success, point mutations emerging before or during TKI treatment remain an obstacle for several cases. T315I is one of these point mutations in the tyrosine kinase domain of BCR::ABL1. It is a major
Oziskender, Renan, Eskazan, Ahmet Emre
openaire +2 more sources
Osteolysis in Chronic Myeloid Leukemia
Tumori Journal, 1978Four patients affected by chronic myeloid leukemia who developed osteolytic lesions in the course of the disease are described. According to the literature, the appearance of these alterations seems to signify an unfavorable prognosis, since they occur slightly before or even at the same time as the blastic transformation of the disease.
G. Lambertenghi-Deliliers +3 more
openaire +3 more sources
Autografting in chronic myeloid leukemia
Seminars in Hematology, 2003Autografting (or autologous stem cell transplant [ASCT]) followed by "rescue" with Philadelphia chromosome (Ph)-negative hematopoietic progenitor cells (HPC) remains a good procedure to guarantee prolonged survival for patients mobilized and autografted soon after diagnosis.
Angelo M, Carella +2 more
openaire +2 more sources
Curing Chronic Myeloid Leukemia
Current Hematologic Malignancy Reports, 2012The use of tyrosine kinase inhibitors (TKIs) targeted against the BCR-ABL1 oncoprotein has proven remarkably successful in chronic myeloid leukemia (CML) and long-term survival has become a reality. Despite this outstanding progress, detection of minimal residual disease precludes therapy termination in most TKI-receiving patients.
Delphine, Rea +4 more
openaire +2 more sources
Current Opinion in Oncology, 1992
Chronic myeloid leukemia is a clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome, involving myeloid, erythroid, megakaryocytic, B lymphoid, and sometimes T lymphoid cells but not marrow fibroblasts.
openaire +3 more sources
Chronic myeloid leukemia is a clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome, involving myeloid, erythroid, megakaryocytic, B lymphoid, and sometimes T lymphoid cells but not marrow fibroblasts.
openaire +3 more sources
Current Opinion in Hematology, 1997
The molecular origin of the BCR-ABL chimeric gene is now reasonably well defined; a new breakpoint cluster region in the BCR gene, designated mu-bcr, has recently been identified. p210BCR-ABL binds with or phosphorylates a wide variety of intracellular proteins but the mechanism by which it exerts its oncogenic potential is not yet known.
openaire +2 more sources
The molecular origin of the BCR-ABL chimeric gene is now reasonably well defined; a new breakpoint cluster region in the BCR gene, designated mu-bcr, has recently been identified. p210BCR-ABL binds with or phosphorylates a wide variety of intracellular proteins but the mechanism by which it exerts its oncogenic potential is not yet known.
openaire +2 more sources
The allometry of chronic myeloid leukemia
Journal of Theoretical Biology, 2009Chronic myeloid leukemia (CML) is an acquired neoplastic hematopoietic stem cell (HSC) disorder characterized by the expression of the BCR-ABL oncoprotein. This gene product is necessary and sufficient to explain the chronic phase of CML. The only known cause of CML is radiation exposure leading to a mutation of at least one HSC, although the vast ...
Pacheco, J., Traulsen, A., Dingli, D.
openaire +3 more sources
JAMA
ImportanceChronic myeloid leukemia (CML) has an annual incidence of 2 cases per 100 000 people and is newly diagnosed in approximately 9300 individuals per year in the US. Approximately 150 000 people in the US and 5 million worldwide have CML.ObservationsChronic myeloid leukemia is a myeloproliferative neoplasm characterized by the presence of the ...
Elias, Jabbour, Hagop, Kantarjian
openaire +2 more sources
ImportanceChronic myeloid leukemia (CML) has an annual incidence of 2 cases per 100 000 people and is newly diagnosed in approximately 9300 individuals per year in the US. Approximately 150 000 people in the US and 5 million worldwide have CML.ObservationsChronic myeloid leukemia is a myeloproliferative neoplasm characterized by the presence of the ...
Elias, Jabbour, Hagop, Kantarjian
openaire +2 more sources

